CD274 and non-small cell lung carcinoma: A meta-analysis (26) further confirmed that while neoadjuvant immunotherapy improved 2-year disease-free survival and pCR rates in NSCLC, these benefits were independent of treatment-related factors such as PD-L1 expression, platinum regimen, or number of cycles.